Why did ALMDT.PA stock fall so sharply pre-market?

ALMDT.PA stock dropped **-17.15%** pre-market on heavy volume. The move follows profit-taking after regulatory headlines and broader biotech volatility. High relative volume (**4.20x**) and short-term technical selling amplified the decline.

What is Meyka AI's forecast for ALMDT.PA stock?

Meyka AI's forecast model projects a 12-month price of **€2.91** for ALMDT.PA stock, implying about **-46.63%** versus the current **€5.46**. Forecasts are model-based projections and not guarantees.

What short-term levels should traders watch for ALMDT.PA stock?

Traders should watch immediate support **€5.42**, 50-day average **€4.27**, and resistance near **€6.87**. High volume and MFI **74.24** suggest elevated short-term volatility.

How does Median Technologies’ financial health affect ALMDT.PA stock?

Median shows negative EPS (**-1.16**) and operating cash flow per share **-€0.72**, with a current ratio **0.35**, indicating liquidity pressure. These facts increase execution risk until revenue and cash flow improve.

EU Stocks

ALMDT.PA Median Technologies down 17.15% pre-market 14 Feb 2026: watch support at €5.42

ByHuzaifa Zahoor February 14, 2026February 14, 2026

ALMDT.PA stock opened the pre-market session sharply lower after a one-day drop of -17.15%, trading at €5.46 on EURONEXT on 14 Feb 2026. Volume has surged to 1,927,008 shares, about 4.20x the average, signalling heavy selling pressure early in the session. The slide follows the company’s recent FDA 510(k) clearance headlines and mixed sector moves, leaving traders focused on near-term support at €5.42 and the 50-day average at €4.27 for clues about a rebound.